Abstract 183P
Background
The incidence of gastric cancer is particularly high in Iran, where it remains a leading cause of cancer-related death, and it is the most common cancer among Iranian men, with an ASR of 21.6 per 100,000 men (GLOBO2018). By contrast the incidence and mortalityof gastric cancer rank fifth and third respectively worldwide. The aim of this study was to evaluate the epidemiologic profile of gastric cancer in East Azerbaijan, Iran.
Methods
In total, 2 years of cancer registry data were collected from different sources in East Azerbaijan (EA-PBCR), and a data quality check was performed to ensure clean data. Using the 2000 World Health Organization standard population, we then generated age-standardized incidence rates (ASRs) for different cancers, with data were generated for each year from 1394 to 1395 of the Persian calendar (i.e., 19 March 2015 to 20 March 2016).
Results
In total we registered 1700 gastric cancer in two years; 918 cases in 2015 and 712 cases in 2016. From these, 1181 cases were male and 519 cases were female, and the male to female ratio was 2.28. The mean age of the patients was 68.45 (±12.97) years, with age range of 21-99 years old. The most common age group was 7th decade with 531 (31.2%) gastric cancer cases. The most common morphological types were adenocarcinoma (n = 667, 39.2%), and intestinal type carcinoma (n = 421, 24.8%), and signet ring cell carcinoma (n = 119, 7%). The age standardized incidence rate (ASR) was 29.65 and 13.30 in males and females per 100,000, in 2015. The ASR was 26.48 and 9.91 in males and females per 100,000, in 2016. Gastric Cancer account for 12.4% of all cancers in both sexes, and the odds for men was 1.50, compared with women (OR 1.50; 95% CI = 1.33 – 1.71). After rigorous attempts, 63.5 % of the cases had microscopic verification (MV), and we collected 3.3 % of reports based on clinical data. The remaining data were collected from the cause of death registry or autopsy records, producing a final DCO% of 27.4%.
Conclusions
The ASR was decreased from 29.7 to 26.48 in men, and decreased from 13.3 to 9.91 in female. However gastric cancer is the most common cancer in terms of incidence and mortality in East Azerbaijan, according to last results of EA-PBCR.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
490P - Outcomes of sequential epidermal growth factor receptor tyrosine (EGFR) tyrosine kinase inhibitor (TKI) therapy in patients with advanced non-small cell lung carcinoma (NSCLC)- a real-world institutional experience
Presenter: Yvonne Ang
Session: Poster display session
Resources:
Abstract
498P - An observational retrospective study to evaluate the incidence of acquired EGFR T790M resistance in NSCLC patients with EGFR mutation following progression after at least one prior EGFR TKI treatment in Taiwan: ARISE study
Presenter: Shang-gin Wu
Session: Poster display session
Resources:
Abstract
501P - Clinical characteristics and efficacy in non-small cell lung cancer patients with EGFR exon 20 insertion and EGFR amplification
Presenter: Xin Gao
Session: Poster display session
Resources:
Abstract
502P - Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced non-small cell lung cancer with uncommon mutations: A multicenter observational study
Presenter: Masaki Kanazu
Session: Poster display session
Resources:
Abstract
482P - Interim analysis from a phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC
Presenter: Filippo De Marinis
Session: Poster display session
Resources:
Abstract
483P - A phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients with EGFR mutation-positive NSCLC: A biomarker analysis
Presenter: Rafael Rosell
Session: Poster display session
Resources:
Abstract
484P - Activity of afatinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC and baseline brain metastases: Pooled analysis of three large phase IIIb trials
Presenter: Maya Gottfried
Session: Poster display session
Resources:
Abstract
491P - Clinical outcomes of leptomeningeal metastases in EGFR-mutant lung adenocarcinoma
Presenter: Chia-I Shen
Session: Poster display session
Resources:
Abstract
510P - Paclitaxel as continuation maintenance therapy in patients with advanced non-small cell lung cancer
Presenter: Suzy Gohar
Session: Poster display session
Resources:
Abstract
496P - Higher osimertinib introduction rate achieved by multiple repeated re-biopsy after acquired resistance to first/second generation EGFR-TKIs
Presenter: Taira Ninomaru
Session: Poster display session
Resources:
Abstract